title: [Hodgkin lymphoma: evolution and dilemma in radiation treatments].
abstract: Multiple new developments in the treatments of patients with Hodkgin lymphoma have occurred in the last 10 years. Radiation treatments have become extremely precise in localized Hodgkin lymphomas, on the other hand, they have almost completely disappeared in advanced stages. For patients with refractory or recurrent disease, it is strongly advocated, whenever feasible, to deliver a mantle field radiation treatment after an autologous stem cell transplant to avoid any further recurrence of the disease.
authors: Département des Radiations, Institut Gustave-Roussy, 94200 Villejuif, France. girinsky@igr.fr
authors: T
authors: T
authors: Girinsky
authors: M
authors: M
authors: Ghalibafian
authors: A
authors: A
authors: Paumier
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D006689:Hodgkin Disease / Q000188:drug therapy / Q000473:pathology / Q000517:prevention & control / Q000532:radiotherapy* / Q000601:surgery; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology / Q000528:radiation effects; D009367:Neoplasm Staging; D011878:Radiotherapy / Q000379:methods* / Q000592:standards / Q000639:trends; D012008:Recurrence; D033581:Stem Cell Transplantation / Q000379:methods
chemical_list: D000970:Antineoplastic Agents